Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa

Authors

Peter U. Fischer, Washington University School of Medicine in St. Louis
Christopher L. King, Case Western Reserve University
Julie A. Jacobson, Bill and Melinda Gates Foundation, Seattle
Gary J. Weil, Washington University School of Medicine in St. Louis

Journal

PLoS Neglected Tropical Diseases

Publication Date

2017

Volume

11

Issue

1

Inclusive Pages

e0005163

Document Type

Open Access Publication

DOI

10.1371/journal.pntd.0005163

Rights and Permissions

Fischer PU, King CL, Jacobson JA, Weil GJ (2017) Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa. PLOS Neglected Tropical Diseases 11(1): e0005163. doi: 10.1371/journal.pntd.0005163

Recommended Citation

Fischer, Peter U.; King, Christopher L.; Jacobson, Julie A.; and Weil, Gary J., "Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa." PLoS Neglected Tropical Diseases. 11, 1. e0005163. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5618